Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: Advanced Human Imaging
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a Form F-1 with the US Securities and Exchange Commission (SEC)
  • The filing relates to the healthcare stock’s proposed initial US public offering of American Depositary Shares (ADS), with each ADS potentially worth 9 AHI listed shares
  • The company would list on the NASDAQ Capital Market under the ticker code AHI, with each ADS to be sold at between US$7 and US$9 each based on the 1 for 9 ratio
  • AHI will begin selling the NASDAQ securities once its registration is accepted by the SEC, which hasn’t occurred at this stage
  • Shares in Advanced Human Imaging are trading up 3.52 per cent at $1.18

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange Commission (SEC).

AHI announced on Wednesday it had submitted a Form F-1 to the SEC in relation to the proposed initial US public offering of American Depositary Shares (ADS).

Each ADS will represent a set number of ordinary AHI shares, though the exact amount is yet to be determined. However, a rough estimate released by the company is that 1 ADS would be worth around 9 AHI securities.

Under the proposed offering, each ADS would be priced at between US$7 and US$9 each and the company would list on the NASDAQ Capital Market under the ticker code AHI.

The healthcare stock will begin selling the NASDAQ securities once its registrations has been accepted by the SEC, which hasn’t occurred at this stage.

The offering will be made via a prospectus and Maxim Group LLC will act as the sole book-running manager under the listing.

Advanced Human Imaging first flagged plans to dual list in the US last year when it signed a funding agreement with Asia Cornerstone Asset Management

Following today’s NASDAQ update, shares in AHI have moved 3.52 per cent in the green to $1.18 per share at 1:47 pm AEDT.

AHI by the numbers
More From The Market Online

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…

Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its brain cancer imaging…

Atomo Diagnostics orders HIV self-test kits for third world countries

Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued…

Imugene expands study for bile tract cancer patients

Imugene will be expanding its trial to treat gastrointestinal cancers - including bile tract cancer -…